학술논문

Prevention of cytomegalovirus disease in moderate-risk (D+/R+ and D-/R+) renal transplant recipients receiving basiliximab induction therapy: an efficacy and safety evaluation of 3 versus 6 months of low-dose valganciclovir
Document Type
Journal
Source
PHARMACOTHERAPY; OCT 2012, 32 10, pE249-pE249, 1p.
Subject
Language
English
ISSN
02770008